Heidelberg Pharma at a glance:

Our facilities situated in the former Max-Planck-Institute in Ladenburg, Germany include 2000 square meters of laboratory space. We are running a dual business model as a pre-clinical CRO and a drug development company.

ADC drug development   CRO
  • As a drug development company we concentrate on combining the targeting properties of antibodies with the effectiveness of an ultra-potent toxin with antibody-drug conjugates (ADC), that are more effective against cancer.
  • Key USP of our technology is the potential to treat multiresistant tumors and ‚dormant or quiescent‘ tumor cells, which are regarded as a main reason for metastasis and resistance.
  • As a pre-clinical CRO we offer explorative pharmacology, drug metabolism and pharmacokinetics (DMPK) analysis and molecular biology.
  • Our core competence is the pre-clinical profiling of small molecules or biologicals destined for the treatment of cancer or inflammatory/autoimmune diseases.